Ranger Investment Management L.P. Trims Stock Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Ranger Investment Management L.P. lowered its holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 2.0% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 577,738 shares of the specialty pharmaceutical company's stock after selling 11,950 shares during the quarter. ANI Pharmaceuticals accounts for 2.0% of Ranger Investment Management L.P.'s holdings, making the stock its 16th largest holding. Ranger Investment Management L.P. owned 2.75% of ANI Pharmaceuticals worth $31,937,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. US Bancorp DE lifted its stake in ANI Pharmaceuticals by 842.9% during the 4th quarter. US Bancorp DE now owns 594 shares of the specialty pharmaceutical company's stock worth $33,000 after acquiring an additional 531 shares in the last quarter. KBC Group NV boosted its stake in shares of ANI Pharmaceuticals by 89.2% in the 4th quarter. KBC Group NV now owns 1,273 shares of the specialty pharmaceutical company's stock valued at $70,000 after buying an additional 600 shares during the period. KLP Kapitalforvaltning AS acquired a new position in ANI Pharmaceuticals during the 4th quarter worth approximately $166,000. HighTower Advisors LLC acquired a new stake in ANI Pharmaceuticals in the third quarter valued at $222,000. Finally, China Universal Asset Management Co. Ltd. lifted its holdings in ANI Pharmaceuticals by 10.2% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 4,457 shares of the specialty pharmaceutical company's stock worth $246,000 after buying an additional 412 shares during the last quarter. 76.05% of the stock is owned by institutional investors and hedge funds.

Remove Ads

ANI Pharmaceuticals Stock Performance

NASDAQ ANIP traded down $0.43 during trading hours on Monday, hitting $67.69. 71,498 shares of the stock were exchanged, compared to its average volume of 267,503. The stock has a 50-day moving average of $62.34 and a 200 day moving average of $59.08. ANI Pharmaceuticals, Inc. has a 12-month low of $52.50 and a 12-month high of $70.00. The company has a market cap of $1.47 billion, a price-to-earnings ratio of -123.07 and a beta of 0.49. The company has a quick ratio of 1.97, a current ratio of 2.74 and a debt-to-equity ratio of 1.52.

Analyst Upgrades and Downgrades

ANIP has been the topic of a number of recent analyst reports. Jefferies Financial Group began coverage on ANI Pharmaceuticals in a report on Friday, March 14th. They issued a "buy" rating and a $80.00 price objective on the stock. StockNews.com cut shares of ANI Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Tuesday, April 8th. JPMorgan Chase & Co. assumed coverage on shares of ANI Pharmaceuticals in a research report on Wednesday, March 12th. They issued an "overweight" rating and a $85.00 price target for the company. HC Wainwright reaffirmed a "buy" rating and set a $94.00 price objective on shares of ANI Pharmaceuticals in a report on Monday, March 17th. Finally, Guggenheim restated a "buy" rating and set a $86.00 price target on shares of ANI Pharmaceuticals in a research note on Friday. One analyst has rated the stock with a sell rating, one has given a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $79.75.

Insiders Place Their Bets

In related news, VP Meredith Cook sold 400 shares of ANI Pharmaceuticals stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $63.33, for a total transaction of $25,332.00. Following the completion of the sale, the vice president now owns 80,545 shares in the company, valued at approximately $5,100,914.85. This trade represents a 0.49 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Krista Davis sold 1,000 shares of ANI Pharmaceuticals stock in a transaction dated Friday, February 21st. The stock was sold at an average price of $60.20, for a total transaction of $60,200.00. Following the sale, the senior vice president now owns 68,624 shares of the company's stock, valued at approximately $4,131,164.80. This trade represents a 1.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 2,800 shares of company stock worth $170,208. Corporate insiders own 12.70% of the company's stock.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.